- Home
- NGNE vs OPOF Comparison
NGNE vs OPOF Comparison
Compare NGNE & OPOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- OPOF
- Stock Information
- Founded
- NGNE 2003
- OPOF 1922
- Country
- NGNE United States
- OPOF United States
- Employees
- NGNE N/A
- OPOF N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- OPOF Major Banks
- Sector
- NGNE Health Care
- OPOF Finance
- Exchange
- NGNE Nasdaq
- OPOF Nasdaq
- Market Cap
- NGNE 251.9M
- OPOF 207.2M
- IPO Year
- NGNE N/A
- OPOF N/A
- Fundamental
- Price
- NGNE $21.83
- OPOF $39.10
- Analyst Decision
- NGNE Buy
- OPOF
- Analyst Count
- NGNE 6
- OPOF 0
- Target Price
- NGNE $39.83
- OPOF N/A
- AVG Volume (30 Days)
- NGNE 224.0K
- OPOF 8.9K
- Earning Date
- NGNE 05-09-2025
- OPOF 07-24-2025
- Dividend Yield
- NGNE N/A
- OPOF 1.43%
- EPS Growth
- NGNE N/A
- OPOF 55.28
- EPS
- NGNE N/A
- OPOF 1.96
- Revenue
- NGNE $925,000.00
- OPOF $61,370,000.00
- Revenue This Year
- NGNE N/A
- OPOF N/A
- Revenue Next Year
- NGNE N/A
- OPOF N/A
- P/E Ratio
- NGNE N/A
- OPOF $19.84
- Revenue Growth
- NGNE N/A
- OPOF 5.28
- 52 Week Low
- NGNE $6.88
- OPOF $13.70
- 52 Week High
- NGNE $74.49
- OPOF $40.88
- Technical
- Relative Strength Index (RSI)
- NGNE 62.53
- OPOF 51.70
- Support Level
- NGNE $16.62
- OPOF $38.76
- Resistance Level
- NGNE $18.90
- OPOF $39.90
- Average True Range (ATR)
- NGNE 2.06
- OPOF 0.83
- MACD
- NGNE 0.38
- OPOF -0.27
- Stochastic Oscillator
- NGNE 60.81
- OPOF 21.59
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About OPOF Old Point Financial Corporation
Old Point Financial Corp functions in the financial services domain in the United States. As the holding company of The Bank and Trust, it is a nationally chartered trust and wealth management service, provider. Its suite of services includes commercial banking solutions such as loan, deposit and cash management, which are rendered through a chain of branches throughout the country. It operates through segments such as Bank, Wealth and Company.